BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success
Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of exclusivity for its blockbuster drugs Eliquis and Opdivo.
BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success Read More »
